Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
The Global Primary Biliary Cholangitis Treatment Market, by Treatment Type (Ursodeoxycholic Acid (UDCA), and Obeticholic Acid (Ocaliva)), and by Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), the market was valued at US$ 526.4 million in 2017, and is expected to exhibit a CAGR of 36.3%, over the forecast period (2018-2026), as highlighted in a new report published by Coherent Market Insights.
Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/2555
The increasing pipeline studies to develop prominent treatments for rare diseases such as primary biliary cholangitis is the factor that is expected to boost the primary biliary cholangitis treatment market growth. For instance, in August 2017, Zydus Discovery DMCC initiated phase 2 clinical trial for Saroglitazar magnesium 2 mg. The aim of the study was to evaluate safety, tolerability, and efficacy of Saroglitazar Magnesium in patients with primary biliary cholangitis (EPICS).The study is estimated to complete by March 2019.
Browse 20 Market Data Tables and 17 Figures spread through 143 Pages and in-depth TOC on “Primary Biliary Cholangitis Treatment Market, by Treatment Type (Ursodeoxycholic Acid (UDCA), and Obeticholic Acid (Ocaliva)), and by Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) – Global Forecast to 2026”
To know the latest trends and insights related to Primary Biliary Cholangitis Treatment market Press Release, click the link below: https://bit.ly/3iwfngG
Major market players are focused on developing therapeutic treatment for the patients with primary biliary cholangitis, which is expected to drive the primary biliary cholangitis treatment market growth over the forecast period. For instance, in March 2015, NGM Biopharmaceuticals, Inc., announced the positive results for phase 2 trial of NGM282 in patients with Primary Biliary Cirrhosis (PBC). NGM282 is an engineered protein variant of human hormone, fibroblast growth factor 19 (FGF19) that maintains bile acid and metabolic regulatory activities as well as eliminates tumorigenic effects of FGF-19. According to the study results, NGM282 is proven to be a potent regulator of bile acid synthesis. Furthermore, in June 2016, Retrophin Inc. acquired ownership of a liquid formulation of ursodeoxycholic acid from Asklepion Pharmaceuticals, LLC. Ursodeoxycholic acid is a naturally occurring bile acid that dissolves gall bladder stone rich in cholesterol and also enhances the flow of bile in primary biliary cholangitis.
Moreover, in February 2018, Intercept Pharmaceuticals, Inc. announced about updated prescribing information for Ocaliva (obeticholic acid or OCA) in the U.S. to emphasize appropriate dosing in primary biliary cholangitis (PBC) patients with Child-Pugh Class B or C or decompensated cirrhosis.
However, lack of awareness among the patients, families and physicians, resulted into delayed diagnosis for rare diseases, which is expected to hamper primary biliary cholangitis treatment market growth over the forecast period. Most of symptoms associated with rare diseases are masked by the symptoms of common illness and may not be detected by doctors.
Key Takeaways of the Primary Biliary Cholangitis Treatment Market:
- The global primary biliary cholangitis treatment market is expected to exhibit a CAGR of 36.3% over the forecast period (2018-2026), attributed to increasing initiatives by the market players to develop prominent treatment options for the treatment of PBC
- The increasing prevalence of PBC in the U.S. is expected to drive growth of the market. For instance, according to the National Center for Biotechnology Information (NCBI) data, the prevalence of PBC from 2006-2016, increased from 21.7 to 39.2 per 100,000 persons in the U.S.
- Key players operating in the global primary biliary cholangitis treatment market include Novartis AG, Bristol-Myers Squibb, NGM Biopharmaceuticals, Lumena Pharmaceuticals, Inc., TARGET PharmaSolutions, Inc., Intercept Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Retrophin, Inc., Calliditas Therapeutics AB, and GlaxoSmithKline (GSK) pharmaceuticals
Apply Promo Code “STAYHOME” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2555
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
